Peripheral T‐cell lymphoma presenting as lipoatrophy and nodules

Yiannias, James A.; DiCaudo, David J.; Maskin, Erik

doi:10.1111/j.1365-4632.2006.02888.x

Cited by 24 publications

(16 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two patients with acquired lipodystrophy who had immunodeficiency documented prior to leptin initiation developed T cell lymphoma after 8 months of leptin therapy. The association of acquired lipodystrophy with T cell lymphoma has been reported in the absence of leptin treatment [14]. While we cannot determine whether leptin therapy played a role in the development of T cell lymphoma, we are concerned about administering leptin to patients with acquired lipodystrophy who have evidence of bone marrow suppression and lymphadenopathy.…”

Section: Resultsmentioning

confidence: 99%

“…We have now observed a second patient with acquired generalised lipodystrophy who developed T cell lymphoma while on leptin replacement. Since T cell lymphoma has been reported in a patient with lipodystrophy [14], we do not know whether the lymphoma is a separate syndrome or whether it may have been affected by leptin treatment. Presently, we are cautious about the use of leptin in patients with acquired forms of lipodystrophy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of leptin therapy in the different forms of human lipodystrophy

et al. 2009

View full text Add to dashboard Cite

Aims/hypothesis Lipodystrophy is a rare disorder characterised by loss of adipose tissue, hypoleptinaemia, severe insulin resistance, diabetes and dyslipidaemia. The aims of this study were to determine whether leptin replacement in lipodystrophy patients ameliorates their metabolic abnormalities over an extended period of time and whether leptin therapy is effective in the different forms of lipodystrophy.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Efficacy of leptin therapy in the different forms of human lipodystrophy

et al. 2009

View full text Add to dashboard Cite

show abstract

“…All cases reported here, as well as two previously published cases 9,10 , are summarized in Table I.…”

Section: Resultsmentioning

confidence: 99%

“…al. reported a 32 year old man who developed panniculitis followed by gradual loss of fat over 7 years leading to generalized lipodystrophy, accompanied by hypertriglyceridemia and increased ALT/AST 10 . Thirteen years later, the patient developed PTCL.…”

Section: Discussionmentioning

confidence: 99%

Lymphoma in acquired generalized lipodystrophy

Brown

Chan

Jaffe

et al. 2015

Leukemia & Lymphoma

View full text Add to dashboard Cite

Acquired generalized lipodystrophy (AGL) is a rare disease thought to result from autoimmune destruction of adipose tissue. Peripheral T-cell lymphoma (PTCL) has been reported in 2 AGL patients. We report five additional cases of lymphoma in AGL, and analyze the role of underlying autoimmunity and recombinant human leptin (metreleptin) replacement in lymphoma development. Three patients developed lymphoma during metreleptin treatment (two PTCL and one ALK-positive anaplastic large cell lymphoma, and two developed lymphomas (mycosis fungoides and Burkitt lymphoma) without metreleptin. AGL is associated with high risk for lymphoma, especially PTCL. Autoimmunity likely contributes to this risk. Lymphoma developed with or without metreleptin, suggesting metreleptin does not directly cause lymphoma development; a theoretical role of metreleptin in lymphoma progression remains possible. For most patients with AGL and severe metabolic complications, the proven benefits of metreleptin on metabolic disease will likely outweigh theoretical risks of metreleptin in lymphoma development or progression.

show abstract

“…12 Additionally, lipoatrophy can occur in the setting of subcutaneous panniculitislike T-cell lymphoma. However, this occurs after the disappearance of preceding skin lesions, presumably as a consequence of a consumptive panniculitis.…”

mentioning

confidence: 99%

Secondary cutaneous marginal zone B-cell lymphoma presenting as lipoatrophy in a patient with hepatitis C

Beck¹,

Paul²,

Sawardekar³

et al. 2014

J Dermatol Case Rep

View full text Add to dashboard Cite

Background: Hepatitis C viral infection is a significant public health problem; 170 million persons are infected worldwide and the prevalence in the southern part of the United States exceeds two percent. Extrahepatic manifestations of hepatitis C viral infection are common; notably, 15-20% of patients will develop cutaneous manifestations of their disease. There are numerous dermatologic diseases associated with hepatitis C infection, including lichen planus, leukocytoclasticvasculitis, and porphyria cutaneatarda.

show abstract

Peripheral T‐cell lymphoma presenting as lipoatrophy and nodules

Abstract: We report a rare case of lymphoma presenting as nodules and profound lipoatrophy, which exemplifies the complexity of lymphomas. Profound lipoatrophy and panniculitis may be an unusual and diagnostically challenging presentation of cutaneous lymphoma.

Cited by 24 publications

References 22 publications

Efficacy of leptin therapy in the different forms of human lipodystrophy

Efficacy of leptin therapy in the different forms of human lipodystrophy

Lymphoma in acquired generalized lipodystrophy

Secondary cutaneous marginal zone B-cell lymphoma presenting as lipoatrophy in a patient with hepatitis C

Contact Info

Product

Resources

About